Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Schizophrenia, recovery, and guided tapering of antipsychotic medication – a qualitative investigation of clinicians’, patients’, and relatives’ perspectives

Projekt: Typer af projekterProjekt

  1. Biomarkers in Clozapine responding Schizophrenia, BiCS

    Projekt: Typer af projekterProjekt

  2. Etablering af ECT database

    Projekt: Typer af projekterProjekt

  • Roed, Kickan (Projektdeltager)
  • Nielsen, Jimmi (Projektleder, organisatorisk)
  • Buus, Niels, Faculty of Medicine, Nursing and Health Sciences at Monash University, Melbourne, Australia, Australien (Projektleder, faglig)
Vis graf over relationer
Treatment with antipsychotic medication is often lifelong for people with schizophrenia. While antipsychotic medications are effective in the treatment of schizophrenia, prolonged treatment (>2 years) is discouraged as side-effects impose a threat to patient’s physical health and constitute a barrier towards the experience of personal recovery. A recent initiative offering guided tapering of antipsychotic medication for people with schizophrenia spectrum disorders indicate that complete or partial tapering of medication is feasible and safe. However, the anticipation of recurrence of symptoms may pose a barrier for promotion of guided tapering in clinical practice. The overall purpose of this Ph.D.-project is to provide an understanding of how guided tapering of antipsychotic medication unfolds in mental health practice. Three studies are proposed: The aim of Study 1 is to describe mental health care professionals’ attitudes towards guided tapering of antipsychotic medication for people with schizophrenia based on focus group interviews. Participants will be approximately 30 medical doctors, psychiatrists, and nurses employed in hospital and community mental health services with a minimum length of employment in mental health services of one year. The aim of Study 2 and 3 is to explore how people with schizophrenia and their relatives, respectively, experience the process of guided tapering of antipsychotic medication, and how this relates to personal recovery. Repeated, individual in-depth interviews will be conducted with approximately 15 people (18-64 years) with schizophrenia spectrum disorders (ICD-10 schizophrenia F20, except for F20.6) undergoing guided tapering of antipsychotic medication (Study 2). Moreover, individual interviews will be conducted with approximately 10 relatives (>18 years of age) of people with schizophrenia spectrum disorders undergoing guided tapering of antipsychotic medication (Study 3). By applying qualitative inquiry, the project will provide an in-depth, nuanced knowledge that will support person-centered evidence-based practice in relation to tapering of antipsychotic medication potentially promoting personal recovery in relation to severe mental illness.
StatusIgangværende
Periode01/01/202231/12/2024
FinansieringskildePrivat fond (Privat)
ForskningsprogramNovo Nordisk
Beløb1.979.250,00 Danske Kroner
Årstal2021

ID: 74074391